247 related articles for article (PubMed ID: 3537125)
1. Immunolocalization and partial characterization of a nucleolar autoantigen (PM-Scl) associated with polymyositis/scleroderma overlap syndromes.
Reimer G; Scheer U; Peters JM; Tan EM
J Immunol; 1986 Dec; 137(12):3802-8. PubMed ID: 3537125
[TBL] [Abstract][Full Text] [Related]
2. Novel aspects of autoantibodies to the PM/Scl complex: clinical, genetic and diagnostic insights.
Mahler M; Raijmakers R
Autoimmun Rev; 2007 Aug; 6(7):432-7. PubMed ID: 17643929
[TBL] [Abstract][Full Text] [Related]
3. Molecular characterization of an autoantigen of PM-Scl in the polymyositis/scleroderma overlap syndrome: a unique and complete human cDNA encoding an apparent 75-kD acidic protein of the nucleolar complex.
Alderuccio F; Chan EK; Tan EM
J Exp Med; 1991 Apr; 173(4):941-52. PubMed ID: 2007859
[TBL] [Abstract][Full Text] [Related]
4. [The PM-Scl (polymyositis-scleroderma) autoantibody and its nucleolar fluorescence pattern].
Kühn G; Jarzabek-Chorzelska M; Blaszczyk M; Kolacinska-Strasz Z; Chorzelski TP; Jablonska S
Dermatol Monatsschr; 1989; 175(8):479-83. PubMed ID: 2676628
[TBL] [Abstract][Full Text] [Related]
5. C1D is a major autoantibody target in patients with the polymyositis-scleroderma overlap syndrome.
Schilders G; Egberts WV; Raijmakers R; Pruijn GJ
Arthritis Rheum; 2007 Jul; 56(7):2449-54. PubMed ID: 17599775
[TBL] [Abstract][Full Text] [Related]
6. Clinical evaluation of autoantibodies to a novel PM/Scl peptide antigen.
Mahler M; Raijmakers R; Dähnrich C; Blüthner M; Fritzler MJ
Arthritis Res Ther; 2005; 7(3):R704-13. PubMed ID: 15899056
[TBL] [Abstract][Full Text] [Related]
7. Antibodies to a nuclear/nucleolar antigen in patients with polymyositis overlap syndromes.
Reichlin M; Maddison PJ; Targoff I; Bunch T; Arnett F; Sharp G; Treadwell E; Tan EM
J Clin Immunol; 1984 Jan; 4(1):40-4. PubMed ID: 6699138
[TBL] [Abstract][Full Text] [Related]
8. PM-Scl-75 is the main autoantigen in patients with the polymyositis/scleroderma overlap syndrome.
Raijmakers R; Renz M; Wiemann C; Egberts WV; Seelig HP; van Venrooij WJ; Pruijn GJ
Arthritis Rheum; 2004 Feb; 50(2):565-9. PubMed ID: 14872500
[TBL] [Abstract][Full Text] [Related]
9. Identification of protein components reactive with anti-PM/Scl autoantibodies.
Gelpi C; Algueró A; Angeles Martinez M; Vidal S; Juarez C; Rodriguez-Sanchez JL
Clin Exp Immunol; 1990 Jul; 81(1):59-64. PubMed ID: 2199097
[TBL] [Abstract][Full Text] [Related]
10. [Antinucleolar antibodies in diagnostics of antiphospholipid syndrome].
Zabek J; Palacz A; Pyka J; Krzewska I
Pol Arch Med Wewn; 2008; 118 Suppl():25-30. PubMed ID: 19562966
[TBL] [Abstract][Full Text] [Related]
11. PM1-Alpha ELISA: the assay of choice for the detection of anti-PM/Scl autoantibodies?
Mahler M; Fritzler MJ
Autoimmun Rev; 2009 Mar; 8(5):373-8. PubMed ID: 19103309
[TBL] [Abstract][Full Text] [Related]
12. Anti-PM/Scl autoantibodies in patients without clinical polymyositis or scleroderma.
Schnitz W; Taylor-Albert E; Targoff IN; Reichlin M; Scofield RH
J Rheumatol; 1996 Oct; 23(10):1729-33. PubMed ID: 8895149
[TBL] [Abstract][Full Text] [Related]
13. [Spectrum of antinuclear and anti-cytoplasmic antibodies in dermatomyositis and polymyositis overlap syndromes].
Meurer M; Hausmann-Martinez-Pardo G; Braun-Falco O
Hautarzt; 1989 Oct; 40(10):623-9. PubMed ID: 2482267
[TBL] [Abstract][Full Text] [Related]
14. Scl-86, a marker antigen for diffuse scleroderma.
van Venrooij WJ; Stapel SO; Houben H; Habets WJ; Kallenberg CG; Penner E; van de Putte LB
J Clin Invest; 1985 Mar; 75(3):1053-60. PubMed ID: 3980727
[TBL] [Abstract][Full Text] [Related]
15. Autoantibody to RNA polymerase I in scleroderma sera.
Reimer G; Rose KM; Scheer U; Tan EM
J Clin Invest; 1987 Jan; 79(1):65-72. PubMed ID: 2432091
[TBL] [Abstract][Full Text] [Related]
16. Serum autoantibody to the nucleolar antigen PM-Scl. Clinical and immunogenetic associations.
Oddis CV; Okano Y; Rudert WA; Trucco M; Duquesnoy RJ; Medsger TA
Arthritis Rheum; 1992 Oct; 35(10):1211-7. PubMed ID: 1418007
[TBL] [Abstract][Full Text] [Related]
17. [The fibrillarin (Scl-34) autoantibody in systemic scleroderma].
Kühn G; Jarzabek-Chorzelska M; Blaszczyk M; Chorzelski TP; Jablonska S
Dermatol Monatsschr; 1990; 176(1):19-26. PubMed ID: 2178987
[TBL] [Abstract][Full Text] [Related]
18. Serological and clinical characterization of anti-dsDNA and anti-PM/Scl double-positive patients.
Mahler M; Greidinger EL; Szmyrka M; Kromminga A; Fritzler MJ
Ann N Y Acad Sci; 2007 Aug; 1109():311-21. PubMed ID: 17785320
[TBL] [Abstract][Full Text] [Related]
19. A highly conserved 72,000 dalton centromeric antigen reactive with autoantibodies from patients with progressive systemic sclerosis.
McNeilage LJ; Whittingham S; McHugh N; Barnett AJ
J Immunol; 1986 Oct; 137(8):2541-7. PubMed ID: 3531335
[TBL] [Abstract][Full Text] [Related]
20. [The Scl-70 antibody and its clinical significance].
Kühn G; Jarzabek-Chorzelska M; Blaszczyk M; Kolacinska-Strasz Z; Chorzelski TP; Jablonska S
Dermatol Monatsschr; 1989; 175(3):133-47. PubMed ID: 2653887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
